AACR Annual Meeting | Conference

Dr. Yohe on the Potential to Target RAS Mutations in Pediatric Cancers

May 17th 2021

Marielle E. Yohe, MD, PhD, discusses the potential utility of targeting RAS mutations in pediatric cancers.

Addition of SDX-7320 to Palbociclib Inhibits Tumor Growth in Breast Cancer Xenografts

April 15th 2021

The addition of SDX-7320, a novel inhibitor of methionine aminopeptidase 2, to palbociclib was found to inhibit MCF-7 tumor growth and reduce the expression of proteins associated with resistance to palbociclib.

Ahuno on Bringing Precision Medicine in Cancer Care to Ghana

April 14th 2021

Samuel Ahuno discusses bringing precision medicine in cancer care to Ghana.

Dr. Matasar on the Efficacy of Copanlisib Plus Rituximab in Indolent NHL

April 14th 2021

Matthew J. Matasar, MD, discusses the efficacy of copanlisib plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma.

Triplet Combos Targeting ER, CDK4/6, and PIK3CA Inhibit Tumor Growth in ER+ Breast Cancer

April 14th 2021

A triplet combination regimen that targets PIK3CA mutations, ER, and CDK4/6 can reduce and inhibit tumor growth in preclinical models of estrogen receptor–positive breast cancer that is resistant to fulvestrant plus a CDK4/6 inhibitor or PI3K inhibitor.

cfDNA Sequencing Shows Utility in Selecting KRAS G12C+ NSCLC for Sotorasib

April 14th 2021

Plasma-based cell-free DNA appears to be a viable strategy comparable with tissue-based testing for selecting patients with KRAS G12C–mutant non–small cell lung cancer for treatment with sotorasib.

Dr. Hassan on the Rationale for Examining Talazoparib Plus Carboplatin in TNBC

April 14th 2021

Saima Hassan, MD, PhD, FRCSC, discusses the rationale for examining talazoparib in combination with carboplatin in patients with triple-negative breast cancer.

Dr. Subbiah on the Efficacy of Selpercatinib in RET Fusion–Positive Cancers

April 13th 2021

Vivek Subbiah, MD, discusses outcomes with selpercatinib in patients with RET fusion–positive cancer.

Neoadjuvant Cemiplimab Elicits Complete Pathological Responses in HCC

April 13th 2021

Significant tumor necrosis was observed in 20% of patients with resectable hepatocellular carcinoma who received neoadjuvant treatment with cemiplimab-rwlc.

Trastuzumab Deruxtecan Benefit/Risk Profile in Advanced Cancer Supported by Pooled Analysis

April 13th 2021

The majority of independently adjudicated interstitial lung disease cases associated with fam-trastuzumab deruxtecan-nxki were low grade and occurred within the first 12 months of treatment, with lower risk of developing the effect observed in patients who were on the drug for longer than 1 year.